Mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene have been identified in families with autosomal dominant Parkinson's disease (PD) and in sporadic cases; the G2019S mutation is the single most frequent. Intriguingly, the frequency of this mutation in PD patients varies greatly among ethnic groups and geographic origins: it is present at <0.1% in East Asia, ∼2% in European-descent patients and can reach frequencies of up to 15 -40% in PD Ashkenazi Jews and North African Arabs. To ascertain the evolutionary dynamics of the G2019S mutation in different populations, we genotyped 74 markers spanning a 16 Mb genomic region around G2019S, in 191 individuals carrying the mutation from 126 families of different origins. Sixty-seven families were of North-African Arab origin, 18 were of North/Western European descent, 37 were of Jewish origin, mostly from Eastern Europe, one was from Japan, one from Turkey and two were of mixed origins. We found the G2019S mutation on three different haplotypes. Network analyses of the three carrier haplotypes showed that G2019S arose independently at least twice in humans. In addition, the population distribution of the intra-allelic diversity of the most widespread carrier haplotype, together with estimations of the age of G2019S determined by two different methods, suggests that one of the founding G2019S mutational events occurred in the Near East at least 4000 years ago. †
INTRODUCTION
Late-onset Parkinson's disease (PD [MIM# 168600]) is a severe, progressive, age-related neurodegenerative disorder with an estimated prevalence of 2% among persons over 65 years of age (1) . It is characterized clinically by bradykinesia, resting tremor, rigidity and postural instability, and neuropathologically by the loss of dopaminergic neurons in the brainstem and the presence of intracytoplasmic inclusions called Lewy bodies in surviving neurons.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene [MIM# 609007 ] at the PARK8 locus [MIM# 607060 ] are the most common known cause of autosomal dominant PD (2, 3) . It has been shown that mutations in the LRRK2 gene can contribute significantly to the etiology of both familial and sporadic PD (4) . LRRK2 is located on chromosome 12q12 and consists of 51 exons. The product of LRRK2, also termed dardarin, is a highly conserved 2527 amino acid protein that has been suggested to be a cytoplasmic kinase involved in neuronal signaling (5) . To date, at least 50 different possibly pathogenic LRRK2 sequence variants have been reported in families presenting a wide variety of clinical and pathological features (6) . The most common and most studied LRRK2 mutation, c.6055 G . A in exon 41, encodes a G2019S change in the highly conserved activation loop of its MAP kinase domain (7 -10) . Haplotype analyses showed that the mutation is found on two distinct haplotypes: a common founder haplotype that is shared by most G2019S carriers and a second haplotype carried by three EuropeanAmerican families, suggesting that the G2019S mutation arose twice in these populations (11) (12) (13) (14) (15) (16) . The first haplotype was reported to derive from a common ancestor estimated to date back 2250 -2600 years, whereas the second appeared more recently (15) . A third haplotype, which differs from the European and North African haplotypes, was identified in three Japanese PD families with the mutation (17, 18) .
Despite the importance of the G2019S mutation in patients with PD and the considerable interest in the evolutionary history of this mutation in the natural setting, it has never been formally tested whether the three G2019S-carrying haplotypes derive from a single founder mutation or from three independent mutational events. In addition, the size of the sample in previous studies (Table 1) , which is critical for a robust estimate of the origin and age of alleles (19) , has been too small to allow for the evaluation of the age of G2019S in different ethnic groups. Indeed, it is now clear that the frequency of G2019S in PD patients depends greatly on their geographic origin: it accounts for 0 to 18% of familial and 0 to 6% of apparently sporadic PD in Europe with a NorthSouth gradient of distribution (20) . It is very rare in East Asia, but accounts for approximately 15 and 40% in Ashkenazi Jews and North African Arabs, respectively (14, (21) (22) (23) (24) (25) (26) (27) (28) . The marked ethnic differences in the risk conferred by G2019S might result from the frequency of G2019S in non-affected populations (i.e. the odds ratio depends on the frequency of the disease-causing variant in controls) (29) , or from different ethnic-related genetic backgrounds, which might include mutations in modifier genes.
Here we sought to assess the evolutionary history of the G2019S mutation in the natural setting, i.e. in a large multiethnic population panel.
RESULTS
To assess the evolutionary history of the G2019S mutation, we first determined the haplotypic phase of the 191 genotyped subjects (382 chromosomes) carrying or not the mutation, for the 74 markers genotyped (see Materials and Methods). Our haplotype data clearly indicated that the G2019S mutation was found on three different haplotypes: haplotype 1, which was the most frequent and widespread (11) (12) (13) (14) (15) (16) 24) ; haplotype 2, which was initially identified in three European-American families only (15) , and was found in two French families in the present study; haplotype 3, which was primarily observed in Japanese PD patients (17, 18) , but also in a Turkish family (30) . Previous studies have shown that these three haplotypes could be distinguished by markers only 5 kb upstream and downstream of G2019S (15, 18) , suggesting that the mutation arose independently in each case.
To formally test whether the G2019S mutation has a single or multiple independent origins, we used our resequencing data from 226 subjects to identify the single nucleotide polymorphisms (SNPs) closest to G2019S that distinguished the three haplotypes (6) . Haplotype 2 differed from haplotype 1 at markers 2.6 kb upstream (rs6581668) and 1.7 kb downstream (rs10506155) of G2019S, and haplotype 3 differed from haplotype 1 at markers 2.6 kb upstream (rs6581668) and 6.2 kb downstream (rs10784522) of G2019S (Supplementary Material, Table S1 ). It is thus highly improbable, given the very short distance separating these SNPs, that haplotypes 2 and 3 were generated by recombination between haplotype 1 and other non-carrier haplotypes. This observation suggests that the G2019S appeared more than once in humans.
To evaluate the phylogenetic relationships between G2019S carrier and non-carrier haplotypes, we reconstructed the network of our haplotype data (see Materials and Methods), restricted to unrelated individuals and to the 32 SNPs contained in the 250 kb interval between D12S2514 and D12S2519 to avoid reticulations in the network due to recombination events or recurrent mutations; Phase estimated that the local recombination rate increased by a factor of 130 at microsatellite D12S2519 (data not shown). Interestingly, the network showed that a non-carrier form of each of the three G2019S-carrying haplotypes was also found at high frequency in the general population (Fig. 1) . In addition, haplotype 1 and haplotypes 2 and 3 were located at the opposite tips of the network, illustrating the high level of divergence among the three haplotypes. Altogether, our results demonstrate that the G2019S mutation occurred independently at least twice during recent human evolution; once on a haplotype 1 background and separately on the evolutionary-related haplotype 2 or 3.
To gain further insight into the history of the G2019S mutation, we estimated the age of the mutation event occurring on haplotype 1; haplotypes 2 and 3 were not studied further because of the small number of individuals carrying these haplotypes. We used two different maximum-likelihood methods to estimate allele age, both based on the distribution of recombination events and the proportion of recombinant haplotypes around the mutation of interest (see Materials and Methods). G2019S was estimated to have appeared on haplotype 1 between 2925 and 6250 years ago, depending on the method and the data used [ To further test this hypothesis, we next studied the population distribution of the intra-allelic diversity of haplotype 1 in more detail. Subjects were grouped according to their ethnic origin. Two subjects were excluded because they were of mixed ancestries (one from South Africa and one from the USA; Supplementary Material, Table S2 ). We built the network of all haplotypes defined as haplotype 1, using all 54 genotyped SNPs. Interestingly, the intra-allelic diversity was not evenly distributed among the different populations studied (Fig. 3) . Haplotypes of North-African Arabs were principally observed in the innermost part of the network, which was the most frequent haplotype and was defined as the ancestral haplotype on which the G2019S mutation appeared. In contrast, the tips of the network corresponded to haplotypes of Ashkenazi Jews (Fig. 3) , which underwent recombination events in the vicinity of the G2019S mutation.
The ethnic-specific distribution of recombining G2019S-carrying haplotypes prompted us to estimate the age of G2019S in each population separately, but using the same definition of the ancestral non-recombining haplotype determined in the whole sample. The two methods showed the age of G2019S to be greater in the Ashkenazi Jewish population [ 
DISCUSSION
In this study, we analyzed in detail the haplotypic diversity of the G2019S mutation responsible for PD in humans, in a large multi-ethnic sample of subjects. Resequencing of the G2019S genomic region as well as phylogenetic analyses of carrier and non-carrier haplotypes clearly support that G2019S occurred independently in humans at least twice, once on the haplotype 1, a widely distributed carrier haplotype, and once on the phylogenetically related haplotypes 2 and 3. Haplotype 2 has been only found in European-descent individuals, whereas haplotype 3 has been observed in few Japanese and Turkish families. However, a complete picture of the geographic distribution of these haplotypes is missing. A larger sample of individuals with haplotypes 2 and 3 would be helpful to determine whether the G2019S mutation also appeared independently on haplotypes 2 and 3.
Our age estimation of the G2019S mutation on haplotype 1 is older than previously reported, especially in Ashkenazi Jews. Generally, this difference with previous studies is likely due to the multi-ethnic origins and the 5-fold greater size of our entire sample (see Table 1 , except for the Ashkenazi sample) (32), rather than the higher marker density in our study, because our estimates were still higher than those previously reported when we restricted our analyses to four SNPs (data not shown). One of the studies, however, estimated the age of G2019S in a large sample of 77 subjects, mostly Ashkenazi Jews, at 1525 years with 95% confidence intervals between 1300 and 1800 (32) . Although our Ashkenazi sample includes 28 of these subjects, our estimation of the age of G2019S in Ashkenazi Jews is much earlier, using the same method and microsatellite data. This difference partially results from the fact that our sample also includes Ashkenazi The number of independent (i.e. identified in unrelated individuals) G2019S-carrying haplotypes analyzed in the study and defined as haplotype 1. b Ages are given in years. The intergenerational time interval was set at 25 years.
c Twenty-six of the 191 individuals genotyped were excluded because their phase reconstructions were of poor quality, 60 were excluded because they were related to at least one other individual, 2 were excluded because they were of mixed origins and 4 carried G2019S haplotype 2 or 3.
2000
Human Molecular Genetics, 2010, Vol. 19, No. 10
Jews from France, in whom the recombination event closest to G2019S was found. This difference also results from our use of a different definition and size of the ancestral nonrecombining haplotype 1. Because of the differences in the ethnic origin of the samples used in our study and in Bar-Shira et al.'s work, we defined the ancestral haplotype from our whole multi-ethnic sample, while Bar-Shira et al.'s group defined it according to their sample of Ashkenazi Jews alone (32) . Consequently, our estimation reflects the age of occurrence of the mutation, while the age estimated by Bar-Shira et al. reflects the founder effect of the mutation in the Ashkenazim. Indeed, when using the definition of the ancestral haplotype used in Bar-Shira et al. Aside from methodological issues, our estimations of the age of G2019S in ancestors of Ashkenazi Jews-ranging from 4500 to 9100 years depending on the method used-do not coincide with current historical records, because the history of the Ashkenazim is probably at most 2000 years old (33, 34) and because other populations of Jewish ancestry do not present the mutation (e.g. Iraqi Jews) (26, 32) . One possible scenario that may explain our results assumes that the LRRK2 mutation initially arose in the Near East-as previously proposed (24)-at least 4000 years ago. Because of a founder effect, the ancestors of present-day Ashkenazi Jews may have kept the low-frequency G2019S mutation through the different diasporas, whereas Near Eastern daughter populations lost the mutation. The mutation might then have been reintroduced by recurrent gene flow from Ashkenazi populations to other Jewish, European and North-African populations. The existence of such gene flows has been demonstrated by phylogeographic studies of mtDNA (33, 34) . The present-day frequency of the mutation in control populations ( 0.05% in Europeans, 0.5% in North-African Arabs and 1% in Ashkenazi Jews) (20) may support this scenario. However, other scenarios might be considered, taking into account the absence of the LRRK2 mutation in other populations of Jewish ancestry (26, 32) .
In conclusion, we have shown using a large multi-ethnic population panel, that the PD-related G2019S mutation has appeared independently in humans at least twice, and that one of these events occurred most likely in the near-East at least 4000 years ago. The late onset of PD and the incomplete penetrance of the G2019S mutation (24) may have prevented elimination of the mutation by negative selection, and it has thus been continuously transmitted since its ancient origin. The higher prevalence of haplotype 1 with respect to haplotypes 2 and 3 is likely due to the earlier origin of haplotype 1, rather than different strengths of negative selection. Indeed, no major differences in the clinical features were noted between patients with haplotypes 1, 2 and 3 Figure 1 . Haplotype network of the LRRK2 G2019S core region in our multi-ethnic panel. Each circle represents a haplotype, the diameter of which is proportional to the haplotype frequency in the sample. Haplotypes in orange carry the G2019S mutation. The numbers in the orange circles indicate the class of the G2019S-carrying haplotypes, as defined in previous studies (12, 13, 15, 18) . Each line connecting two haplotypes represents a mutational event. The length of lines is proportional to the number of mutational events. Lines in orange correspond to the appearance of G2019S. We restricted this analysis to unrelated individuals and to the 32 SNPs located between the D12S2514 and D12S2519 microsatellites to avoid reticulations in the network due to recombination events or recurrent mutations. Interestingly, haplotype 1 and haplotypes 2 and 3 were located on each edge of the network, suggesting multiple origins of the G2019S mutation. 17, 26, 28, 35, 36) . However, the small number of families sharing haplotypes 2 and 3 does not allow detecting significant differences between these three groups. Further studies of large samples of affected and unaffected individuals from different human populations will help understand the strong ethnic variation in the risk of PD conferred by this mutation.
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MATERIALS AND METHODS

Study populations
This population data set was mostly derived from 1230 unrelated patients with PD and 391 control individuals recruited from the French PD genetic study group and diverse collaborations within the Mediterranean basin. All patients met standardized diagnostic criteria for PD and were examined by a movement disorder specialist. Blood samples were obtained from all participants with their informed consent. In all, we assembled a series of 125 index cases with the G2019S mutation (120 heterozygous and 5 homozygous) and one control carrier (the spouse of a PD patient who did not carry the LRRK2 G2019S mutation). Most of these G2019S-positive families have been reported elsewhere (13, 14, 17, 26, 28, 30, 35, 37, 38) . Additional members of 16 of the families (22 affected and 43 unaffected) were included in the present study. Of the 126 families, 67 were of North-African Arab origin (54 from Algeria, 10 from Morocco and 3 from Tunisia), 18 were of North/Western European descent (12 from France, 2 from Portugal, 2 from Italy, 1 from Belgium and 1 from the Netherlands), 37 were of Jewish origin, including 32 Ashkenazi Jews (10 from Poland, 4 from Romania, 4 from Russia, 3 from Byelorussia, 3 from the Ukraine, 2 from Germany, 2 from Hungary, 3 from France and 1 expatriate family from South Africa) and 5 Sephardic Jews (3 from Algeria, 1 from Tunisia and 1 from Morocco), 1 family was from Japan, 1 from Turkey and 2 families were of mixed ancestries (1 from South Africa and 1 from the USA).
Marker selection and genotyping
In addition to the 25 markers previously described (12, 15) , we designed four additional short tandem repeat (STR) and 45 SNP markers within the 16 Mb LRRK2 region delimited by the D12S2194 and D12S2520 STR markers (Supplementary Material, Table S1 ) (primer sequences and PCR conditions upon request). The 4 STRs-D12S(CAAA) n , (AG) n , (AT) n and (TA) n -were identified using the program Tandem Repeats Finder (39 
Statistical analyses
The haplotypic phase of all 191 genotyped subjects (382 chromosomes, with or without the G2019S mutation) was obtained using the Bayesian method implemented in Phase v.2.1.1 (40) . We divided the phasing procedure into three steps, because some of the individuals sampled were related and some data were missing (28 Ashkenazi patients from Northern/Eastern Europe were genotyped for a subset of only 41 markers). First, we phased markers without missing data in related individuals (with family data), specifying in Phase the parent/child relationships. The haplotypes of this first step were reconstructed with 100% confidence. Second, we phased markers without missing data in all unrelated individuals (without family data), together with one child per family whose haplotypes were retrieved from the first step and set as 'known haplotypes' in the second step. This second step was run 10 times with different seeds and the most probable run was kept. Third, we phased all markers in all unrelated individuals, retrieving the phase at markers without missing data from the second step and specifying that their phase is known. This third step was run 10 times with different seeds and the most probable run was kept. Missing genotypes were imputed by Phase. Sixty related individuals and 26 unrelated individuals with a low maximal probability of haplotype pairs (,10%) were discarded from subsequent analyses. Our final data set was composed of 105 individuals, including 105 G2019S-carrier haplotypes and 105 non-carrier haplotypes. Network reconstruction of all carrier and non-carrier haplotypes was obtained using the median-joining algorithm implemented in NETWORK v.4.5.1 (41) . G2019S allele age was calculated using two different methods. The first method, designed for SNP data, assumes a null mutation rate and uses the recombination rate only as a molecular clock (42) . The second approach, which was implemented in Estiage and designed for microsatellite data, uses both the mutation and recombination rates as molecular clocks (43) . Local recombination rates were obtained from the HapMap II recombination map for SNPs (44) , and from the Map-O-Mat database for microsatellites, when available. The two maps were congruent with each other. Rates that were not available were extrapolated from physical distances using a scale of 0.55 cM per Mb (estimated from the physical and genetic distances between D12S2194 and D12S1301). A stepwise mutation rate at 10 23 mutations per site per generation (45) was used in Estiage to model mutations of microsatellites. We used a 25-year intergeneration interval for both methods. 
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